STOCK TITAN

Acurx Pharmaceuticals Inc - ACXP STOCK NEWS

Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.

Company Overview

Acurx Pharmaceuticals Inc (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company dedicated to advancing a revolutionary class of small-molecule antibiotics. With a focus on antimicrobial innovation and a Gram-positive selective spectrum (GPSS®), Acurx is engineering novel compounds that inhibit the DNA replication of difficult-to-treat bacteria. Utilizing advanced targeting of DNA polymerase IIIC, the company strives to combat pathogens that have been designated as priority by global health authorities.

Core Business and Technology

The company’s research and development efforts are anchored in its pioneering approach to antibiotic discovery. Acurx Pharmaceuticals develops molecules that selectively disrupt the bacterial enzyme DNA polymerase IIIC, which is critical for the replication of Gram-positive bacteria. This targeted mechanism not only works to eradicate infections caused by organisms such as Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and drug-resistant Streptococcus pneumoniae (DRSP), but also minimizes collateral damage to the host microbiome. By preserving beneficial bacteria, this approach potentially lowers recurrence rates of infections and delivers a competitive edge in antibiotic therapy.

Pipeline and Product Candidates

Acurx’s leading product candidate, ibezapolstat, is designed to treat Clostridioides difficile infections. Ibezapolstat represents the first in a new class of DNA polymerase IIIC inhibitors, which exhibits a narrow-spectrum activity that is intended to reduce adverse effects on the gut microbiome compared to traditional broad-spectrum antibiotics. The company is actively engaged in clinical trials to validate the efficacy and safety of this compound, with regulatory communications and milestones reflecting a solid foundation for the upcoming Phase 3 studies.

Scientific and Clinical Approach

The firm’s commitment to innovation is evident in its integration of advanced scientific methodologies and in silico genomic analyses. By identifying variant sites in bacterial targets, Acurx refines its compounds to ensure optimal binding and selectivity. This comprehensive approach not only supports the clinical development of ibezapolstat but also lays the groundwork for the discovery of additional systemically absorbed candidates that may treat other critical Gram-positive infections, including those related to bioterrorism concerns.

Competitive Landscape and Market Position

Acurx Pharmaceuticals occupies a distinctive niche within the biopharmaceutical industry. Unlike many traditional antibiotic developers, the company emphasizes precision targeting of bacterial replication mechanisms. This focus on preserving essential aspects of the human microbiome distinguishes its products from conventional therapies such as vancomycin and metronidazole, which often disrupt beneficial flora. Through its robust R&D pipeline and multiple granted patents across key markets, Acurx is positioned as an informed and innovative player in the fight against antibiotic resistance.

Operational Strategy and Future Insights

While the company maintains a neutral stance on forecasting future performance, it is clear that Acurx places significant emphasis on meticulous regulatory planning, comprehensive clinical evaluations, and strategic patent protection. These activities not only enhance investor understanding but also establish a solid framework for responsible antibiotic innovation. Investors and industry experts interested in the advancement of novel antimicrobial therapies will find Acurx’s scientific and clinical strategies to be a valuable case study in contemporary biopharmaceutical development.

Key Attributes at a Glance

  • Innovative Targeting: Utilizes DNA polymerase IIIC inhibition to combat Gram-positive bacteria.
  • Microbiome Preservation: Designed to minimize disruption of beneficial gut flora.
  • Rigorous Clinical Evaluation: Progressing through clinical stages with a focus on treating C. difficile infections.
  • Patent Portfolio: Secures proprietary technologies across multiple international jurisdictions.
  • Expert-Led Research: Collaborates with top scientific institutions to validate targeted antibiotic activity.

Conclusion

In summary, Acurx Pharmaceuticals Inc exemplifies a forward-thinking, scientifically driven approach in the development of antibiotic therapies. Its focus on narrowly targeted, small-molecule candidates designed to address challenging Gram-positive infections places the company at the intersection of innovation and clinical necessity. This comprehensive overview serves as a valuable resource for investors, analysts, and healthcare professionals seeking an in-depth understanding of Acurx’s operations, business model, and competitive positioning within the biopharmaceutical landscape.

Rhea-AI Summary

Acurx Pharmaceuticals (NASDAQ:ACXP), a late-stage biopharmaceutical company focused on developing novel small molecule antibiotics, has announced its participation in The Microcap Conference. The event will be held from January 28-30, 2025, at the Borgata Hotel in Atlantic City, New Jersey. David P. Luci, President & CEO, will deliver the company's presentation on Wednesday, January 29, 2025, at 10 am ET. The company specializes in developing treatments for difficult-to-treat bacterial infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.99%
Tags
conferences
-
Rhea-AI Summary

Acurx Pharmaceuticals has provided updates on the Phase 3 readiness of its lead antibiotic candidate, ibezapolstat, for treating C. difficile Infection (CDI). The FDA has given positive feedback on the proposed Chemistry Manufacturing and Controls (CMC) plan, and Acurx is awaiting final advice from the European Medicines Agency (EMA) for the Phase 3 clinical program in the EU. The company is also discussing pediatric development plans with both the FDA and EU authorities. Acurx is preparing to request regulatory guidance for initiating clinical trials in Japan, Canada, and the UK.

Phase 3 international trial planning is advancing, utilizing AI to identify optimal clinical trial sites. Ibezapolstat has previously received FDA QIDP and Fast-Track Designation and SME designation from the EMA. The Phase 3 trial will involve approximately 450 subjects, comparing ibezapolstat to vancomycin, with a focus on achieving clinical cure and reducing CDI recurrence. The Executive Chairman expressed confidence in the trial's success, which would pave the way for US NDA submission and EU Marketing Authorization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18%
Tags
-
Rhea-AI Summary

Acurx Pharmaceuticals (NASDAQ: ACXP) announced that its Board of Directors has approved the purchase of up to $1 million in Bitcoin as a treasury reserve asset. The company views this as a strategic move for cash not needed in the next 12-18 months, citing Bitcoin's growing demand, acceptance as a major asset class, and inflation-resistant characteristics. The company emphasized that this financial strategy will not affect their core drug development plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.77%
Tags
management
Rhea-AI Summary

Acurx Pharmaceuticals (NASDAQ: ACXP) participated in the Peggy Lillis Foundation's Inaugural CDI Scientific Symposium, presenting updated Phase 2b clinical data for ibezapolstat. The company is preparing to advance its lead antibiotic candidate into international Phase 3 clinical trials for C. difficile Infection (CDI) treatment. Dr. Kevin Garey presented microbiome results showing ibezapolstat promotes beneficial bacteria growth while avoiding harmful Proteobacteria overgrowth. The FDA has agreed on key elements for two Phase 3 pivotal trials, requiring approximately 450 subjects in the Modified Intent-To-Treat population, randomized 1:1 between ibezapolstat and vancomycin.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
-
Rhea-AI Summary

Acurx Pharmaceuticals (NASDAQ: ACXP) reported Q3 2024 financial results and business updates. The company ended Q3 with $5.8 million in cash, down from $7.5 million in December 2023. Q3 net loss was $2.8 million ($0.17 per share), compared to $3.1 million ($0.24 per share) in Q3 2023. Key developments include FDA submission for CMC meeting to commence Phase 3 trials, new patent grant for ibezapolstat extending to 2042, and positive Phase 2 trial results presentation showing comparable efficacy to vancomycin. The company raised $1.6 million through ATM financing during the quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
-
Rhea-AI Summary

Acurx Pharmaceuticals (NASDAQ: ACXP) presented new bile acid and microbiome analyses from their Phase 2b trial of ibezapolstat for C. difficile Infection (CDI) at the IDWeek 2024 Conference. The data showed a favorable gut bile acid profile and restoration of beneficial bacteria in ibezapolstat-treated patients, which may contribute to its anti-recurrence effect. Ibezapolstat demonstrated comparable clinical cure rates and safety to vancomycin, with no recurrence in the 5 patients followed for 3 months post-treatment.

Acurx is preparing to advance ibezapolstat into international Phase 3 clinical trials for CDI treatment, following a successful FDA End-of-Phase 2 Meeting. The company plans to submit requests for regulatory guidance in the EU, UK, Japan, and Canada. Ibezapolstat has previously received FDA QIDP and Fast-Track Designation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
none
Rhea-AI Summary

Acurx Pharmaceuticals (NASDAQ: ACXP), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, has announced its participation in the Spartan Capital inaugural investor conference on November 4, 2024, at the Pierre Hotel in New York. The company's CEO, David P. Luci, expressed enthusiasm about the opportunity to showcase Acurx's accomplishments and future plans to key influencers in the capital markets.

The conference, organized in partnership with B2i Digital, will feature presentations from over 30 selected companies, along with panel discussions, one-on-one meetings, and networking sessions. This event aligns with Acurx's commitment to engage with industry leaders and investors, providing a platform to offer insights into the company's growth strategy and market position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
none
-
Rhea-AI Summary

Acurx Pharmaceuticals (NASDAQ: ACXP), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, has announced that it will discuss its third quarter 2024 financial results on Wednesday, November 13, 2024, at 8:00 am ET before the U.S. financial markets open. The company's President and CEO, David P. Luci, along with CFO Robert G. Shawah, will host a conference call to discuss the results and provide a business update.

Interested parties can join the call using the following details:
- Toll-free (U.S.): 877-790-1503
- International: Participant international Toll-Free access numbers available via provided link
- Conference ID: 13749688

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

New to The Street, a leading U.S. business television platform, has renewed its media partnership with Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), a late-stage biopharmaceutical company. The new series includes broadcast television interviews, earned media placements, and a comprehensive outdoor advertising campaign.

Acurx Pharmaceuticals will be featured on New to The Street's national television broadcasts, highlighting the company's latest developments and leadership in addressing critical bacterial infections through innovative antibiotics. The coverage will air across major networks, enhancing Acurx's visibility in the biopharmaceutical sector.

The partnership also includes targeted earned media placements and outdoor advertising support, featuring billboard placements in strategic locations like Times Square and the Financial District. The media series is set to begin airing immediately in 2024, with outdoor and earned media elements running concurrently to maximize audience reach.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
none
Rhea-AI Summary

New to The Street announces its upcoming sponsored programming on Bloomberg TV, airing Saturday, October 12, at 6:30 PM EST. The lineup features innovative companies including ZAPP, NUBURU, and ACURX Pharmaceuticals, showcasing advancements in electric vehicles, blue laser technology, and antibiotic innovation respectively. The program will also include The Sustainable Green Team highlighting eco-friendly solutions for environmental sustainability, and SEKUR returning with its "Hack of the Week" segment, focusing on cybersecurity threats and privacy protection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
none

FAQ

What is the current stock price of Acurx Pharmaceuticals (ACXP)?

The current stock price of Acurx Pharmaceuticals (ACXP) is $0.33 as of April 3, 2025.

What is the market cap of Acurx Pharmaceuticals (ACXP)?

The market cap of Acurx Pharmaceuticals (ACXP) is approximately 7.9M.

What is Acurx Pharmaceuticals’ core focus?

Acurx Pharmaceuticals focuses on developing new classes of small molecule antibiotics, particularly targeting Gram-positive bacteria that cause difficult-to-treat infections.

How does Acurx differentiate its antibiotics from traditional treatments?

The company’s lead candidate, ibezapolstat, blocks DNA polymerase IIIC in Gram-positive bacteria, offering narrow-spectrum activity that preserves beneficial gut microbiota, reducing recurrence rates.

What types of infections are targeted by Acurx’s pipeline?

Their pipeline predominantly targets infections caused by Clostridioides difficile, MRSA, VRE, and drug-resistant Streptococcus pneumoniae, which are significant challenges in clinical settings.

What is ibezapolstat and why is it significant?

Ibezapolstat is Acurx’s lead antibiotic candidate designed to treat C. difficile infections. Its novel mechanism of action aims to disrupt bacterial DNA replication while maintaining the balance of the gut microbiome.

What stage is Acurx’s clinical development currently in?

The company is in the late clinical stage, actively preparing for international Phase 3 clinical trials, supported by robust clinical data and regulatory feedback.

How does Acurx ensure the preservation of the gut microbiome?

Acurx’s targeted approach focuses on a narrow spectrum of activity that spares beneficial bacteria, reducing typical side effects associated with broader-spectrum antibiotics.

Which regulatory bodies are involved in reviewing Acurx’s developments?

Acurx collaborates with major regulatory agencies including the FDA and EMA, following stringent clinical and non-clinical guidelines to support its antibiotic candidates.

How does Acurx’s technology contribute to combating antibiotic resistance?

By targeting specific bacterial enzymes with precision, Acurx’s compounds provide an innovative solution to antibiotic resistance, offering potential treatments for infections that no longer respond to conventional therapies.
Acurx Pharmaceuticals Inc

Nasdaq:ACXP

ACXP Rankings

ACXP Stock Data

7.92M
19.47M
11.67%
9.8%
2.32%
Biotechnology
Pharmaceutical Preparations
Link
United States
STATEN ISLAND